Sir, in their review of the diagnosis and management of oral candidosis, 1 Lewis and Williams raise the issue as to whether antifungal therapy prior to biopsy for suspected chronic hyperplastic candidosis (CHC) will enable the histopathologist to state whether any epithelial atypia which is identified microscopically is genuine dysplasia or merely a reactive change to the infection.
Unfortunately, pre-biopsy antifungals might complicate rather than simplify matters, since the histological changes in the oral mucosa caused by candidal infection may persist even after antifungal medication but without any demonstrable fungal hyphae, even with special stains. The problem in this situation is that the microscopic features of candidal infection are not specific and might prompt the pathologist to consider other diagnostic possibilities such as non-specific chronic hyperkeratosis and inflammation, migratory stomatitis/glossitis (ie geographic tongue) or rare entities such as irritant contact stomatitis, plasma cell stomatitis, Reiter's syndrome and psoriasis, a potentially misleading differential diagnosis that could confuse subsequent clinical management.
On the other hand there are occasions when, as the reporting oral pathologist, I add 're-biopsy after antifungal therapy might be helpful' at the end of the histopathology report if, in the presence of histologicallyproven candidal infection, I have been unable to decide whether there is genuine epithelial dysplasia or not. Some cases of CHC resolve after anti-fungal medication and thus re-biopsy is not justifiable on clinical (or ethical) grounds. It is assumed that in such cases the epithelial atypia was indeed reactive, but the possibility also exists that anti-fungal therapy cures genuine dysplasia in some patients with CHC. 
